Projects

InOpSys

Sector
Circular Economy
Line of Business
Flexible and mobile units for wastewater treatment
Founders
AvOre (Steven De Laet) and Raf De Wil
Registered Office
12A Zandvoortstraat,
2800 Mechelen

InOpsys develops and builds flexible, modular and mobile units for onsite toxic wastewater treatment. This unique concept combines expertise, the use of existing and clean technologies as well as a new approach to waste management. In this way, InopSys helps chemical and pharmaceutical industries to reach their sustainable development goals.

The expertise comes from the KU Leuven, the technologies are acquired on the market or developed by AvoRe (one of the founders of InOpSys). The innovative approach consists of bringing the installation to the location where the water has to be treated by truck (Plant-On-A-Truck).

For more information: InOpSys

Innovation Fund Investment

On 18 December 2015, the Innovation Fund and Gemma Frisius invested EUR 500,000 each in InOpSys.

VMH joined the shareholders in September 2018 and provided further funding together with the existing shareholders.

Lisam

Sector
Processes, Information Technology
Line of Business
Management services for legal documents and reports on the environment, health and safety for different industrial sectors including chemistry.
Founders
Thierry Levintoff and Michel Hemberg
Registered Office
42A Boulevard de la Sennette,
7190 Ecausinnes

Combining a flexible technology that is easy to use, based on the Microsoft .NET platform with the latest regulatory content, Lisam provides innovative, affordable and rapid solutions to the environment, health and safety (EHS) challenges faced by manufacturers, distributors and users of chemical and cosmetic products.

In cooperation with the associations and partners from industry, Lisam has developed proprietary and vertical EHS solutions for chemicals, chemical speciality products, cosmetics, aromas, detergents, paints, coatings, plastics and the energy industries. Today, more than 900 customers in industry count on the Lisam flagship software, ExeSS®, to manage their safety datasheets and their labels, designed for all the main commercial markets and available in 50 languages.

For more information: Lisam

Innovation Fund Investment

On 28 January 2016, the Innovation Fund invested EUR 250,000 in LISAM.

PharmaFluidics

Sector
Processes – molecular separation and analysis
Line of Business
New generation liquid chromatography column
Founders
Paul Jacobs, Wim De Malssche, Gert Desmet and Joeri Denayer
Registered Office
Technologiepark, 3 Zwijnaarde,
9052 Zwijnaarde

PharmaFluidics is a spin-off of the Dutch-speaking Free University of Brussels (VUB) and has benefited from initial PMV/SOFI and Qbic financing to the tune of EUR 1.25 million.
The company has developed a new type of liquid chromatography columns (in the field of mixture separation and analysis) which shows a significant advantage compared to existing columns: ease of use, standardisation, efficacy and potential development to measure.

The company is refining these columns further, has obtained recommendations from laboratories and opinion leaders in the field, and markets them in the biotech, pharmaceutical and chemical industries.

For more information: PharmaFluidics

Innovation Fund Investment

On 9 May 2016, the Innovation Fund invested EUR 199,992 in PharmaFluidics. Further investments were made in 2017 and are expected going forward. The Fund’s stake in the capital is 9.63%

TrendMiner – Sold to Software AG – June 30th, 2018

Sector
Processes, Information Technology
Line of Business
Industrial process analysis, monitoring and prediction application
Founders
Bert Baeck, Noël Jans, Thomas Dhollander and Tom Coen
Registered Office
297 Kempische Steenweg B3,
B-3500 Hasselt

TrendMiner has developed an application which analyses and monitors in real time the temporal series of production parameters. TrendMiner is used to predict certain production anomalies by relying on the (predictive) recognition of historical patterns and search of similar historical patterns to help explain the causes of production deviances. TrendMiner “learns” by relying on parameters provided by the operator.

For more information: TrendMiner

Innovation Fund Investment

On 10 May 2016, the Innovation Fund decided to invest EUR 1,000,000 in TrendMiner.

X4C

Sector
Materials Technology
Line of Business
Application of a single layer in calix (4) arene for post-functionalisation.
Founders
Alice Mattiuzzi
Registered Office
(French-speaking) Free University of Brussels (ULB)
Organic Chemistry Laboratory
50 Avenue Franklin Roosevelt CP160/06
B-1050 Brussels

X4C has developed a new technology for applying a single layer on a substrate and for the post-functionalising of the substrate. This concept leads to a strong covalent bond between the substrate and the functional element.

The technology was developed in the organic chemistry laboratory of the Free University of Brussels under the direction of Professor Ivan Jabin.

For more information: X4C

Innovation Fund Investment

On 18 March 2016, the Innovation Fund decided to invest EUR 30,000 in X4C. This investment is contingent upon the finalisation of the licensing agreement with the Free University of Brussels. An additional investment is planned for 2017, depending on the results of the first commercial steps.

Fyteko

Sector
Biosciences
Line of Business
Development of a bio-stimulant to foster resistance to abiotic stress in crops
Founders
Juan Carlos Cabrera Pino, Guillaume Wegria
Registered Office
Allee de la Recherche 4
1070 Bruxelles
Belgium

Fyteko has discovered a molecule that induces better resistance to abiotic stress in a number of crops.

The scientific research was carried out by the founders.

For more information: Fyteko

Innovation Fund Investment

On September 29th, 2016, the Innovation Fund invested in Fyteko. The investment will help Fyteko register and market its first molecule while encouraging further research into formulation and molecules.

Mathym – Sold to Baikowski SA – September 30th, 2019

Sector
Materials Technology
Line of Business
Nanomaterials in colloidal solutions
Founders
Frederic Chaput, Julien Alberici
Registered Office
22 rue des Aulnes
69410 Champagne-au-Mont-d’Or
France

Mathym has developed a technology to produce easy and safe to use colloidal nanoparticles as ingredients in medical composite materials. The first products came on the market in 2017.

The underlying research was carried out by Frederic Chaput at ENS Lyon and Essilor.

For more information: Mathym

Innovation Fund Investment

The Innovation Fund invested alongside Octalfa, Kreaxi and two business angels to support the industrialization of the technology and the marketing of Mathym’s first product

Aerosint

Sector
Materials Technology
Line of Business
3D Printing/additive manufacturing
Founders
M4ke.it, Matthias Hick, Edouard Moens, Kevin Eckes
Registered Office
Rue des Poles 1
4000 Liege
Belgium

Aerosint is working on an industrial prototype that improves the material efficiency of SLS 3D printing. Aerosint is collaborating with a number of blue chip companies to bring multimaterial 3D printing to the market.

For more information: Aerosint

Innovation Fund Investment

The Innovation Fund invested alongside Noshaq to support the move from proof of concept to industrial prototype.

Proceedix

Sector
Processes, Information Technology
Line of Business
Procedures, work instructions and checks made paperless and mobile
Founders
Peter Verstraeten, Steven Serneels
Registered Office
Ottergemsesteenweg Zuid, 808
Ghelamco Arena - Meet District
9000 Ghent

Proceedix develops, markets and sells a digital solution to enable procedures, work instructions and checks to be carried out paperless and mobile. The software allows to very easily transform paper instructions into a set of digital instructions. The level of details of the various steps can be adjusted by the operator according to his/her level of experience and/or comfort.

Proceedix works best as a cloud solution and is tailored for visualisation on desktops, laptops, phones, tablets or smartglasses.

For more information: Proceedix

Innovation Fund Investment

The Innovation Fund invested together with Saffelberg Investments, Pentacon and the management to fund the go to market.

Iristick

Sector
Processes, Information Technology
Line of Business
Wearables
Registered Office
Lamorinierestraat, 123
2018 Antwerpen

Iristick designs smartglasses for the industry. The Iristick qualifies as safety glasses, can be fitted with prescription glasses and allows the user to handle complex tasks while communicating hands-free, getting instant access to information and sharing data with other operators.

For more information: Iristick

Innovation Fund Investment

The Innovation Fund partnered with Saffelberg Investments, Pentacon and the management to fund the commercial launch of Iristick.

AllerInvest

Sector
Biosciences
Line of Business
Allergies
Founders
Anne-Catherine Mailleux, Pierre Buffet
Registered Office
Clos Chapelle aux Champs 30
1200 Bruxelles

AllerInvest commercialises through pharmacists a kit to prevent allergies to dustmites. The regular application of the treatment to the bedding reduces the allergic response of the patient and allows him or her to sleep much better.

For more information: Acar’up

Innovation Fund Investment

The Innovation Fund invested alongside Inventures, Theodorus and My Micro Invest to fund the commercial expansion of Acar’Up.

Blue Foot Membranes

Sector
Materials Technology
Line of Business
Back washable flat sheet membrane
Founders
Patrick Vanschoubroek, VITO
Registered Office
Gerard Mercatorstraat 31
3920 Lommel

Blue Foot Membranes is a start-up company producing and commercialising the unique and worldwide-patented Integrated Permeate Channel (IPC™) technology.
IPC™ membranes are the worlds first fully back washable flat sheet membranes. Installed in existing as well as in new membrane bioreactor, IPC™ membranes can double the output capacity per square meter and lower the aeration cost by at least 50% of your existing or future MBR.

For more information: Blue Foot Membranes

Innovation Fund Investment

The Innovation Fund invested with LRM, Qbic and Dow to finance the industrialisation of the production and the commercial roll out of the IPC™ membrane.

Rein4ced

Sector
Materials Technology
Line of Business
Reinforced carbon fibres
Founders
Michael Callens and Niels De Greef
Registered Office
Diependaalweg 4a
3020 Winksele
Belgium
REIN4CED will manufacture impact-resistant and lightweight bicycle frames for bicycle brands wishing to offer their cyclists maximum performance with enhanced safety and durability. Carbon fiber composites, known from Formula 1 and race bikes, are light and strong but face sudden, brittle and dramatic fracture behavior. To tackle this problem, REIN4CED has developed and patented a brand new composite material. With this new material, and a completely new fully automated production process, REIN4CED will offer safe, durable and lightweight bicycle frames. The initial focus is on the bicycle market, followed by automotive and aerospace.
For more information: Rein4ced

Innovation Fund Investment

The Innovation Fund invested with Gemma Frisius and Finindus to finance the validation of a full bicycle frame, the industrialisation of the production and the commercial roll out of Rein4ced’s new material.

TheraVet

Sector
Biosciences
Line of Business
Veterinary products
Founders
Enrico Bastianelli
Registered Office
Rue Auguste Piccard 48
6041 Charleroi
Belgium

TheraVet  is a biotech start-up company, created in November 2017 which develops innovative treatments for high unmet medical need osteoarticular conditions (e.g. bone, joint, tendon/ligament) for small companion animals such as dogs. TheraVet’s mature product portfolio is composed of innovative synthetic, biological and cellular products developed from clinical stage and marketed human products.

 

Innovation Fund Investment

The Innovation Fund invested together with Theodorus III, InvestSud affiliates and business angels in TheraVet to fund the execution of clinical trials and move the veterinarian products in development closer to market.

Zeopore Technologies

Sector
Materials Technology
Line of Business
Catalysts
Founders
Danny Verboekend, Martin d'Halluin, Bert Sels, Bert Lagrain, Carl Van Camp
Registered Office
Lelielaan 4, 3061 Leefdaal (Bertem)

Zeopore Technologies NV is a start-up company developing and commercialising a unique and proprietary zeolite “mesoporisation” technology, that significantly improves their efficiency in catalytic refining and petrochemical processes. Its key differentiator is the ability to retain the intrinsic properties of the zeolite, while performing the “mesoporisation” via an industrially and economically viable process.

The main benefits are a higher output of desired chemical products, combined with a lower energy and raw materials consumption, leading to a significantly better performance of the customers production process.

 

For more information: www.zeopore.com

Innovation Fund Investment

The Innovation Fund and Gemma Frisius fund invested in Zeopore to finance the piloting and scale up of Zeopore’s “mesoporisation” technology. The technology will allow chemicals and petrochemical companies to improve their production yields, resulting in better usage and higher transformation efficiency of raw materials.

Univercells

Sector
Biosciences
Line of Business
Manufacturing
Founders
Jose Castillo and Hugues Bultot
Registered Office
Rue Auguste Picard 48
6041 Gosselies
Belgium

Univercells is a technology company delivering novel biomanufacturing platforms to make biologicals available and affordable to all.

Univercells provides customisable solutions for viral production (human and veterinary vaccines, gene therapy vectors, oncolytic viruses), biosimilar monoclonal antibodies and enzyme replacement therapies.

The technology aims to significantly reduce the infrastructure footprint to offer cost-effective production of high-quality biologicals for small to medium size markets.

For more information: http://www.univercells.com

Innovation Fund Investment

The Innovation Fund invested together with Global Health Investment Fund, Korea Investment Partners, Inventures II and TheClubDeal to fund the development of two public health vaccines and the commercialisation of of a diversified portfolio of technology solutions.

Aloxy

Sector
Processes, Information Technology
Line of Business
Industrial process analysis, monitoring and prediction application
Founders
Maarten Weyn, Jan Coppens, Carl Stevens and Glenn Ergeerts
Registered Office
The Beacon
Sint-Pietersvliet 7
2000 Antwerp
Belgium

Aloxy offers a modular IIoT platform for the process and chemical industry.

Aloxy provides tools to improve safety and efficiency, automate processes and to deliver actionable insights into industrial operations.

The initial product line consists of a wireless position sensor for manual valves and a platform to monitor the status of assets during shutdowns and regular maintenance.

Aloxy is a spin-off of imec and University Antwerp.

For more information: http://www.aloxy.io

Innovation Fund Investment

The Innovation Fund invested together with Qbic, Cronos, Engie Fabricom and University Antwerp to help transform the proof of concept into roll outs and secure Atex certification for the sensor as well as fund the development of new applications.

AgriProtein

Sector
Circular economy
Line of Business
Transformation of organic waste into protein, oil and chitin
Founders
Johan Jacobs
Registered Office
Registerde Office in Belgium:

Slachthuisstraat 120/6, 2300 Turnhout
Circular Organics has proven at small size mastering the technology for the transformation, through the black soldier fly, of organic waste into valuable nutrients for animals and products for the chemical industry.
In December 2018, insect technology pioneer AgriProtein, named as one of TIME magazine’s Top 50 Genius Companies, has agreed to a friendly take-over of Circular Organics.
AgriProtein will start financing the first full-scale factory in Belgium in 2019.
For more information: www.agriprotein.com

Innovation Fund Investment

Innovation Fund has invested in Millibeter prior the takeover by AgriProtein, to strengthen the position of Belgium in the worldwide group. A second Belgian plant and the European R&D centre will be established in Belgium in the coming years.

Daphne Technology

Sector
Processes, Circular economy
Line of Business
Emissions reduction
Founders
Mario Michan, Bjorn Asplind, EPFL
Registered Office
Chemin de la Venoge 7
CH-1025 Saint-Sulpice, Vaud
Switzerland

Daphne Technology SA is a spin-off from The École polytechnique fédérale de Lausanne (EPFL) incorporated in 2017 with headquarters at the EPFL Innovation Park.

Daphne’s technology is being developed with support from the Swiss Plasma Center and the European Center for Nuclear Research (CERN). Daphne is currently industrializing its technology in collaboration with a leading European shipping company and expects to start marketing its scrubbers in 2019.

Daphne’s technology transforms air pollutants into valuable by-product, reducing operating expenses in a sustainable manner.

 

Innovation Fund Investment

The Innovation Fund invested together with Saudi Aramco Energy Ventures and a number of private investors in Daphne on December 20th, 2018. The investment will help Daphne get certification of its scrubber.

DoseVue

Sector
Medical devices
Line of Business
Dosimtery equipment for cancer therapy
Founders
Emiliano d'Agostino, SCK-CEN

DoseVue was established in 2013 as a spin-off company of the Belgian Nuclear Research Centre (SCK-CEN) with the aim of developing innovative technologies for convenient and accurate quantification of irradiation doses in the course of medical interventions.

For more information: www.dosevue.com

Innovation Fund Investment

In December 2018, The Innovation Fund participated to a financing round togheter with SCK-CEN and Limburgse Reconversie Maatschappij (LRM). This round aimed at financing its next stage of product development. As a result of the Innovation Fund owns c. 28% of DoseVue

PurVer

Sector
Recycling technologies
Line of Business
Organic waste processing
Founders
Jean-Pierre Tondreau, Gembloux Agro-Biotech
Registered Office
2 Passage des Déportés
5030 Gembloux
Belgium

PurVer produces and sells vermicompost and derived products. PurVer is to become the European leader in that market.

 

For more information: www.PurVer.be

Innovation Fund Investment

Innovation Fund invested in PurVer alongside S.R.I.W. Environnement and CFEP to accelerate the investments and the growth of this capital intensive business en bring it to the level of profitability.

Graftys

Sector
Bio Sciences
Line of Business
Bone cements

Graftys develops, manufactures and markets patented synthetic orthopedic biomaterials, in particular a new generation of resorbable calcium-phosphate cements for reconstructive surgery. The bone cement market is one of the fastest growing sgements of the orthopedic market. The company’s key products – Graftys® Quickset fast setting/high viscosity and Graftys® HBS lower viscosity/high injectability cements – are commercialized in more than 25 countries, including Europe and the United States of America.

For more information: Graftys

Innovation Fund Investment

In February 2019, Innovation Fund participated in a financing round with Noshaq, Go Capital and TheClubDeal. This €4.1m funding round will be used for commercial efforts, R&D in Nantes and  production facilities in Charleroi and Liège.

Tools4Patient

Sector
Bio Sciences
Line of Business
Individual patient response characterisation in clinical research
Founders
Dominique Demolle, Alvaro Pereira and Chantal Gossuin
Registered Office
11 Rue Granbonpré
1348 Louvain-La-Neuve

Tools4Patient addresses the interferences caused by individual response in new therapies clinical research. Its objective is to reduce the failures of clinical tests due to placebo effect, hence reducing the cost of clinical research.

Placebell is the first product marketed.

For more information: Tools4Patient

Innovation Fund Investment

Together with Sambrinvest, Innovation Fund invested in Tools4patient in April 2019.

Apaxen

Sector
Biosciences
Line of Business
Pre-clinical stage biotechnology
Founders
Gael Jalce (PhD), based on a patent co-developed with INSERM and Paris-Sud University
Registered Office
Brussels South Charleroi Biopark
Rue Adrienne Bolland 8
6041 Charleroi
Belgium

Apaxen is a preclinical stage biotechnology company developing unique anti-inflammatory therapeutics with a primary focus on pulmonary arterial hypertension (PAH). It developed a first-in-class small molecule inhibitors of pleiotropic pro-inflammatory cytokine “Macrophage migration Inhibitory Factor (MIF)”, a crucial regulator of innate immune responses. Apaxen’s lead compound MFC-1040 has a unique mechanism of action and has the potential to revolutionise the standard of care of PAH and other diseases related to chronic inflammation.

For more information: Apaxen

Innovation Fund Investment

In July 2019, The Innovation Fund participated to a €3.3 million in a Series A funding round together with Theodorus, Sambrinvest, Innovation Fund, Financière Spin-off Luxembourgeoise and members of “Be Angels”. As a result of the Innovation Fund owns c. 13%.

Norimat

Sector
Materials Technology
Line of Business
Spark Plasma Sintering process
Founders
Romain Ephere and Yannick Beynet
Registered Office
51 rue de l'innovation
31670 Labège (Toulouse)
France

Created in 2016, Norimat has developed an innovative over-moulding process based on Spark Plasma Sintering technology (SPS). The company uses breakthrough technology developed by the CIRIMAT laboratory (CNRS Toulouse).

The company currently exploits five different patents. All these skills around the SPS process are sold to clients in the aeronautics, aerospace, defence or luxury industry.  In Europe, Norimat is the first player to bring out SPS flash sintering “from the laboratory” to a industrial level.

For more information: Norimat

Innovation Fund Investment

In July 2019, The Innovation Fund participated to a Series A funding round together with Galia Gestion and IRDI SORIDOC Gestion. As a result of the Innovation Fund owns c. 12% of the company.

Secoya Technologies

Sector
Process Technology
Line of Business
Continuous productions technologies for the pharmaceutical sector
Founders
Pr. Benoit Scheid, Adrien Dewandre, Youen Vitry, Jean Septavaux, Bart Rimez, Olivier André
Registered Office
Fond des Més 4,
1348 Ottignies-Louvain-la-Neuve
Belgium

Secoya Technologies is a spin-off of ULB. It has a portfolio of 4 technologies covering the key steps of the drug production process: continuous reactions, crystallisation, pervaporation and droplet generation.

The unique value proposition of Secoya is to:

(i) bring down these unit operations at the sub-millimetric scale to take benefit of a rigorous control of the operating conditions;

(ii) rely on continuous processing and smart scale-up to ensure production rates compatible with industrial needs; and

(iii) offer 4 complementary technologies.

Secoya will develop more synergies between the different steps.

Innovation Fund Investment

On 22 November 2019, Innovation Fund together with private investors invested 1.050.000 € in Secoya Technologies, joining ULB and the founders in the capital. Proceeds will be used to launch the company.

Fluigent

Sector
Process Technology
Line of Business
Microfluidics
Founders
Jean-Louis Viovy and Jacques Lewiner
Registered Office
67 Avenue de Fontainebleau
94270 Le Kremlin-Bicêtre
France

Fluigent is a French company leader in controlling accurately pressure and flow in multiple channel chips. Fluigent was the first company to introduce pressure pumps to the microfluidic research market, as opposed to conventional syringe pumps. Today, Fluigent develops, manufactures and supports the most advanced microfluidic full pressure and flow-rate control systems available, designed for coupled multi-channel configurations.

More information: Fluigent

 

Innovation Fund Investment

In November 2019, The Innovation Fund participated in a funding round with Inventures. As a result, The Innovation Fund owns c. 6% of the company.